Moreover, the panelists emphasized that real-world evidence goes beyond clinical trial data. It involves continuous patient monitoring, proactive adverse effect management, and adapting protocols ...

Discover why insurance coverage matters for precision medicine and what solutions can improve equitable, personalized ...

Researchers have identified type 5 collagen as a key factor in kidney fibrosis, revealing its potential as a biomarker to predict chronic kidney disease progression. A repurposed anti-cancer drug, ...

The NIMML Institute, ("NIMML"), a 501 (c)(3) nonprofit institute dedicated to the discovery of novel precision medicines for inflammatory and autoimmune diseases, will present results from two novel ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Academy of Neurology (AAN) ...

Avicanna Inc. ("Avicanna" or the "Company) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to ...

VANCOUVER, BC / ACCESS Newswire / April 3, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned ...

Leading artificial intelligence (AI) driven drug discovery and bioinformatics, Dr. Sita Sirisha Madugula is making ...

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, ...

Deep Bio, a pioneer in AI-powered digital pathology, will present new research at the American Association for Cancer ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations ...

Secondary endpoints in the MINDFuL trial include the CDR-SB, E-Cog, ADL and Neuropsychiatric Inventory (NPI) instruments, along with blood biomarker and neuroimaging outcomes. Baseline demographics, ...